8-K: Relmada Therapeutics Faces Nasdaq Delisting Threat After Share Price Falls Below $1

Relmada Therapeutics has received a notification from Nasdaq that its stock price has fallen below the required minimum of $1 per share, placing it at risk of delisting.

Summary

• Relmada Therapeutics received a notice from Nasdaq on January 21, 2025, stating that its stock price had not maintained a minimum bid price of $1 for 30 consecutive business days.
• The company has been given a 180-day compliance period, ending on July 21, 2025, to regain compliance.
• To regain compliance, the stock price must close at or above $1 for at least ten consecutive business days during the compliance period.
• Relmada may also consider a reverse stock split, which must be completed no later than ten business days before the end of the compliance period.
• If the company fails to regain compliance, its stock may be delisted from the Nasdaq Global Market, or it may be allowed to transfer to the Nasdaq Capital Market if it meets the criteria.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting notice) and uncertainty about the company's ability to regain compliance. While the company expresses intent to take action, the overall tone is concerning.

Positives

• The company intends to actively monitor its bid price and take all reasonable measures to regain compliance.
• The company has the option to transfer to the Nasdaq Capital Market if it meets the listing criteria.

Negatives

• The company's stock price has fallen below the minimum bid price of $1, triggering a delisting notice from Nasdaq.
• There is no guarantee that the company will be able to regain or maintain compliance with Nasdaq listing standards.
• The company faces the risk of being delisted from the Nasdaq Global Market if it fails to regain compliance.

Risks

• The company may not be able to regain compliance with the minimum bid price requirement.
• Delisting from the Nasdaq Global Market could negatively impact the company's stock price and investor confidence.
• The company's ability to raise capital may be affected if it is delisted.
• There is no guarantee that the company will be able to transfer to the Nasdaq Capital Market.

Future Outlook

The company intends to actively monitor its bid price and take all reasonable measures to regain compliance with Nasdaq listing requirements. There is no guarantee that the company will be able to regain or maintain compliance with the applicable continued listing standards.

Management Comments

• The company intends to actively monitor the company's bid price during the Compliance Period and intends to take all reasonable measures available to regain compliance with the requirements for continued listing on the Nasdaq Global Market.

Industry Context

This announcement is not uncommon for companies that experience a significant drop in their stock price. Many companies in the biotech sector face similar challenges, especially during periods of market volatility or when clinical trial results are not favorable. Delisting can have a significant impact on a company's ability to raise capital and maintain investor confidence.

Comparison to Industry Standards

• Many biotech companies, especially those in the development stage, face challenges in maintaining their stock price above the minimum bid price required by exchanges like Nasdaq.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have faced similar delisting threats in the past, highlighting the volatility and risk associated with the biotech sector.
• The 180-day compliance period is a standard procedure for Nasdaq, giving companies time to address the issue.
• Reverse stock splits are a common strategy used by companies to regain compliance, but they can also be viewed negatively by investors.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment.
• Employees may be concerned about the company's future.
• The company's ability to raise capital may be affected.
• The company's reputation may be negatively impacted.

Next Steps

• The company will actively monitor its bid price.
• The company will take all reasonable measures to regain compliance with Nasdaq listing requirements.
• The company may consider a reverse stock split.
• The company may explore transferring to the Nasdaq Capital Market.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, reverse stock split, RLMD, Relmada Therapeutics, stock price